Passage Bio, Inc. is facing potential delisting from The Nasdaq Stock Market due to non-compliance with listing requirements. The company reported stockholders' equity of only $50,000, significantly below the $2.5 million minimum required for continued listing. This situation arises as Passage Bio prepares to merge with Remix Therapeutics, a move that could potentially restore its compliance.

On November 12, 2026, Passage Bio received a notification letter from Nasdaq's Listing Qualifications Department, indicating that it did not meet the equity requirement outlined in Nasdaq Listing Rule 5550(b)(1). The company has been actively pursuing a merger that it believes will help it regain compliance and improve its financial standing.

Background

Passage Bio, Inc. is a Delaware-based company engaged in the development of biological products, specifically within the realm of gene therapies. The firm trades on the Nasdaq under the ticker symbol PASG. As a smaller reporting company, it has been navigating the complexities of the biotechnology sector, which is classified under SIC code 2836, focusing on biological products without diagnostic substances.

What the Filing Says

The recent filing indicates that Passage Bio is currently not in compliance with Nasdaq's continued listing standards due to insufficient stockholders' equity. The company stated, "Passage Bio expects to complete its previously announced mergers with Remix Therapeutics, Inc., which is expected to improve its financial metrics and regain compliance with Nasdaq requirements." The filing also noted that the letter from Nasdaq does not have an immediate effect on the trading of the company's stock.

Impact

This development may affect various stakeholders, including investors, employees, and partners. Investors may be concerned about the company's ability to maintain its listing and the potential volatility of its stock price. Employees and management are likely focused on the successful completion of the merger with Remix Therapeutics, which could stabilize the company's financial position and future growth prospects.

What's Next

The company plans to proceed with the merger with Remix Therapeutics, which is expected to close as soon as possible, following the satisfaction of remaining conditions. If the merger does not close within the stipulated time frame, Passage Bio intends to submit a plan to regain compliance with Nasdaq's listing rules. The filing does not specify an exact timeline for these developments.